#153223

Anti-CD21 [BU80]

Cat. #153223

Anti-CD21 [BU80]

Cat. #: 153223

Unit size: 100 ug

Availability: 3-4 weeks

Target: CD21

Class: Monoclonal

Application: IHC

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Margaret Goodall

Institute: University of Birmingham

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-CD21 [BU80]
  • Alternate name: Complement receptor type 2; CR2; complement C3d receptor, C3DR, Epstein-Barr virus receptor
  • Research fields: Immunology
  • Clone: BU79
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC
  • Description: Cluster of differentiation 21 (CD21) is a protein encoded by the CR2 gene in humans. It is involved in the complement system and binds to iC3b (an inactive derivative of C3b). B cells are known to have CR2 receptors on their surfaces allowing the complement system to act in B-cell maturation and activation. Genetic variations are associated with susceptibility to systemic lupus erythematosus type 9 (SLEB9) which is a chronic autoimmune disease with an inflammatory, and often febrile multisystemic disorder of connective tissue characterized principally by involvement of the skin, joints, kidneys, and serosal membranes.
  • Immunogen: Daudi cell line (B lymphoblast)
  • Isotype: IgG1

Target Details

  • Target: CD21
  • Target background: Cluster of differentiation 21 (CD21) is a protein encoded by the CR2 gene in humans. It is involved in the complement system and binds to iC3b (an inactive derivative of C3b). B cells are known to have CR2 receptors on their surfaces allowing the complement system to act in B-cell maturation and activation. Genetic variations are associated with susceptibility to systemic lupus erythematosus type 9 (SLEB9) which is a chronic autoimmune disease with an inflammatory, and often febrile multisystemic disorder of connective tissue characterized principally by involvement of the skin, joints, kidneys, and serosal membranes.

Applications

  • Application: IHC

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Leucocyte Typing IV, (1989): edited by W. Knapp, OUP, Oxford.
  • Leucocyte Typing V, (1995): edited by S.F. Schlossman, OUP, Oxford.
  • Leucocyte Typing VI, (1998): edited by T. Kishimoto, Garland Publishing, New York.